Cue Biopharma, Inc. (CUE) News

Cue Biopharma, Inc. (CUE): $3.72

-0.06 (-1.59%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add CUE to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

D

Ranked

#75 of 168

in industry

Filter CUE News Items

CUE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CUE News Highlights

  • For CUE, its 30 day story count is now at 7.
  • Over the past 28 days, the trend for CUE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BODY, EYE and VIEW are the most mentioned tickers in articles about CUE.

Latest CUE News From Around the Web

Below are the latest news stories about CUE BIOPHARMA INC that investors may wish to consider to help them evaluate CUE as an investment opportunity.

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York. The Company will provide a corporate update highlighting the most recent clinical progress for CUE-101, its lead

Yahoo | June 5, 2023

3 Biotech Stocks Sitting on Huge-Upside Catalysts

The biotech boom is hot.

Ian Cooper on InvestorPlace | May 26, 2023

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have tumor burden reductions of -18% and -24% and remain on treatment100% of patients treated with CUE-101+ pembrolizumab at the recommended phase 2 dose (RP2D) of 4mg/kg (n=16) remain alive to date following treatment As of the data cutoff date, CUE-1

Yahoo | May 25, 2023

Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the presentation of a poster at the American Society of Clinical Oncology (ASCO) Ann

Yahoo | May 15, 2023

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 9, 2023

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and financial update for the first quarter 2023. Recent Business Highlights CUE-101 abstract accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for Ju

Yahoo | May 9, 2023

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023. During the fireside chat, Cue Biopharma will provide an update on ongoi

Yahoo | May 8, 2023

7 Hot Growth Stocks Poised to Triple in 2023

These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.

Alex Sirois on InvestorPlace | May 5, 2023

7 High-Potential Penny Stocks in the Biotech Sector

Most of the biggest biotech stocks on the market started off as unknown penny stocks.

Ian Cooper on InvestorPlace | May 4, 2023

Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in d

Yahoo | April 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6767 seconds.